Your essential biotech, medtech, and pharma recap — no noise, just what matters.

⚡ Executive Takeaway

When Lilly acquired Ajax for $2.3B in April, the deal was a bet on a Phase 1 asset with no clinical data. Van Naarden told investors that proof-of-concept data would come later in 2026. It arrived on June 13. The Type II JAK2 inhibitor "started working right out of the gate," per Van Naarden, with a safety profile that appears manageable. This is the first clinical validation that binding JAK2 in the Type II conformation, rather than the Type I conformation used by all approved JAK2 inhibitors (ruxolitinib, fedratinib, pacritinib, momelotinib), produces meaningful clinical activity in myelofibrosis patients. If the data hold through dose optimization and registrational development, Lilly will have a differentiated blood cancer franchise targeting the resistance population that current therapies cannot adequately address. This is Lilly's 12-deal, $30B+ M&A strategy producing its first clinical proof point beyond the GLP-1 franchise. Meanwhile, AstraZeneca's Truqap approval in PTEN-deficient prostate cancer is significant for precision oncology. PTEN loss occurs in a significant proportion of metastatic prostate cancers but has not been actionable until now. Having a biomarker-matched treatment changes how these patients are managed and creates demand for PTEN testing, which benefits the diagnostics sector. 👉 Read Full Analysis

🔮 What To Watch

🔬 Clinical & Research Updates

Ajax JAK2 Inhibitor Shows Early Clinical Activity in Myelofibrosis LLY

Fierce Biotech reported on June 13 that early data from Lilly's Ajax Therapeutics Type II JAK2 inhibitor (AJ1-11095) showed the drug "started working right out of the gate, with a good safety profile." Lilly Oncology president Jake Van Naarden shared the results. AJ1-11095 is a first-in-class oral once-daily inhibitor that binds the Type II (inactive) conformation of JAK2, distinct from all approved JAK2 inhibitors which bind the Type I (active) conformation. The drug is designed to deliver deeper disease control and address resistance in patients who have progressed on existing therapies. Lilly acquired Ajax for up to $2.3B in April. The Phase 1 AJX-101 trial (NCT06343805) is enrolling patients with myelofibrosis who have been previously treated with a Type I JAK2 inhibitor.

AstraZeneca Truqap Approved as First Targeted Treatment for PTEN-Deficient Prostate Cancer AZN

The FDA approved AstraZeneca's Truqap (capivasertib) in combination with abiraterone and prednisone on June 13 for adult patients with PTEN-deficient metastatic castration-sensitive prostate cancer (mCSPC), according to The Pharma Letter. This is the first and only targeted treatment approved for this molecularly defined prostate cancer population. PTEN loss, which occurs in a significant proportion of metastatic prostate cancers, drives resistance to standard hormonal therapies. Truqap is an AKT inhibitor that targets the PI3K/AKT pathway activated by PTEN deficiency. The approval creates a companion diagnostic requirement for PTEN testing, expanding the diagnostics opportunity in prostate cancer.

🏢 Capital Markets

Kardigan Sets IPO Terms at Up to $373M for Cardiac Drug Pipeline

Kardigan Therapeutics set terms for an IPO that could raise up to $373M, according to BioPharma Dive. The company would be the 13th biotech to go public in 2026, with a pipeline of clinical-stage cardiovascular programs. The cardiac focus is notable: cardiovascular biotechs have been underrepresented in the 2026 IPO wave, which has been dominated by oncology and metabolic disease companies. Kardigan's debut follows AstraZeneca's Baxfendy approval (first new hypertension mechanism in two decades), the new AHA/ACC LDL guidelines, and the asundexian NDA acceptance, all of which signal renewed investor appetite for the cardiovascular space.

🔬 Hematology

EHA 2026 Wrap: AbbVie Venetoclax Data

The European Hematology Association congress wrapped up in Stockholm (June 11 to 14). AbbVie presented new Phase 3 data on a fixed-duration venetoclax-based combination in hematologic malignancies, according to The Pharma Letter. Venetoclax (Venclexta) is a cornerstone of AbbVie's hematology franchise and continues to expand its label through new combination regimens and fixed-duration treatment protocols. EHA also featured updates on CAR-T real-world outcomes, bispecific antibodies in myeloma, and emerging cell therapies.

🔬 Gene Therapy & Diagnostics

Sensorion Exits Hearing Loss Gene Therapy After Otarmeni Approval

BioPharma Dive reported that Sensorion ended development of its gene therapy for OTOF-related hearing loss, citing a "notably changed" development environment. The change is directly attributable to Regeneron's Otarmeni, which was approved under CNPV in April as the first gene therapy for genetic hearing loss. Sensorion's exit illustrates how fast-follower programs can become unviable once a first-mover secures approval and establishes the treatment paradigm. For the diagnostics sector, the Otarmeni approval creates demand for OTOF gene testing in newborns, an emerging opportunity in genetic screening.

📋 The Week in Review

📅 The Week Ahead

When we covered the Lilly/Ajax $2.3B acquisition on April 28, we noted: "Lilly is paying $2.3B for a preclinical thesis that has not been proven in humans. The data later this year will determine whether this was a visionary acquisition or an overpay."

The data are here. Van Naarden says it is working. The early signal validation matters for two reasons:

For Lilly: It confirms the Type II JAK2 mechanism has clinical activity, reducing the probability that the $2.3B was spent on a drug that does not work in humans. The path to registrational development is now open.

For the field: All approved JAK2 inhibitors bind Type I. If Type II binding proves to deliver deeper, more durable responses, it validates an entirely new approach to treating myelofibrosis and potentially other myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia).

Next steps: dose optimization in the Phase 1 expansion, followed by Phase 2/3 design. The registrational trial will likely focus on patients who have failed Type I JAK2 inhibitors, a clearly defined resistance population with high unmet need.

💊 Precision Oncology: PTEN in Prostate

Truqap's approval creates a new clinical workflow:

This is the first time prostate cancer treatment has been stratified by a molecular biomarker beyond androgen receptor status. For diagnostics companies (Foundation Medicine, Guardant, Natera, Exact Sciences), PTEN testing becomes a reimbursable clinical requirement for a significant proportion of metastatic prostate patients.

📊 The Cardiovascular IPO Signal

Kardigan's $373M terms mark the first cardiovascular-focused biotech IPO of significant size in 2026. The cardiac space has lagged oncology and metabolic disease in both deal activity and public market interest. But the fundamentals are improving:

Kardigan's ability to raise $373M in a cardiovascular IPO signals that investors are starting to value cardiac innovation at the same multiples they have historically reserved for oncology and rare disease.

🎯 Catalyst Calendar: June 2026 Forward

👉 Visit The Pro Hub

Is your company listed in the BioMed Nexus directory? 2,104 companies across 14 categories. Claim or upgrade your listing →

Sponsorship slots for 2026 are limited. See packages and pricing →

NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →